
Assistant Professor @UWCarbone. Proud @WinshipAtEmory, @uiccom, @slusom, @XavierU alum. Clinical investigator focusing on myeloma and plasma cell disorders.
Madison, WI
Joined July 2018
- Tweets529
- Following756
- Followers954
- Likes1.6K
Timothy Schmidt, MD retweeted
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
Timothy Schmidt, MD retweeted
Answering the Transplant Question for Newly Diagnosed Patients - The FAS... youtu.be/4dO24XN1zUU?is=H66F… via @YouTube
Timothy Schmidt, MD retweeted
***COMMIT Publication Alert***
British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/…
Timothy Schmidt, MD retweeted
ASH has released new Clinical Practice Guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening bone marrow disorder. The guidelines present 12 evidence-based recommendations designed to help clinicians improve diagnosis.
ow.ly/OMEV50Y4S71
Timothy Schmidt, MD retweeted
#Myeloma Paper of the Day: American Society of Hematology (ASH) 2026 guidelines on diagnosis of light chain/AL #amyloidosis emphasizing serum & urine immunofixation, serum free light chains, and surrogate biopsies (both bone marrow and fat pad): pubmed.ncbi.nlm.nih.gov/4159…. #mmsm
Timothy Schmidt, MD retweeted
💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update
If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0:
📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower grades.
🧪 Neutrophils:
Grade 1 Gone: ANC 1000–1500 is now Grade 1 (was G2). The old Grade 1 (1500–LLN) is no longer graded.
Stricter G4: threshold drops from <500 to <100/mm³.
🩸 Platelets (Thrombocytopenia):
Wider G3: Now covers 10k–50k (previously 25k–50k).
Stricter G4: threshold drops from <25k to <10k/mm³.
v6.0 also adds "transfusion indicated" to Grade 3 and "urgent intervention indicated" to Grade 4 criteria.
Overall, IMO these new thresholds align better with clinical practice.
#ClinicalTrials #MedEd #OncTwitter #DrugSafety
Timothy Schmidt, MD retweeted
All CoMMit active trials and past research is now in one place. Learn more about and support our work. commitmyelomatrials.org
Timothy Schmidt, MD retweeted
Real-world data provide a CARbon copy for ide-cel #mmsm #bmtsm @TMSchmidtMD @BloodPortfolio ashpublications.org/blood/ar…
Timothy Schmidt, MD retweeted
#Myeloma Paper of the Day: Comparison of standard-of-care Ide-cel and Cilta-cel in relapsed/refractory myeloma finds Cilta associated w/ higher likelihood of grade ≥3 CRS, SPMs, and delayed neurotox, but better treatment responses, PFS, and OS: pubmed.ncbi.nlm.nih.gov/3996…. #mmsm
Timothy Schmidt, MD retweeted
How do you approach patients with AL amyloidosis with high plasmacytosis in the bone marrow (ex. 35%) but no other evidence of myeloma?
27%DaraCyBorD->Dara
63%DaraCyBorD->ASCT if poss
5%DaraCyBorD->Dara+(V or R)
5%Other
111 votes • Final results Timothy Schmidt, MD retweeted
Tune in to our new episode on quadruplets in newly diagnosed transplant-ineligible #Myeloma with @TMSchmidtMD! 🎙️ We break down the IMROZ & BENEFIT trials and how to apply them in our current practice. 🩺🔍
share.transistor.fm/s/6e20d2…
Check out this short clip!
Timothy Schmidt, MD retweeted
Coming soon! Episode on newly diagnosed transplant-ineligible #MultipleMyeloma & in-depth analysis of 𝐈𝐌𝐑𝐎𝐙 and 𝐈𝐅𝐌-𝟐𝟎𝟐𝟎/𝐁𝐄𝐍𝐄𝐅𝐈𝐓 trials with @TMSchmidtMD!
#EHA24 #ASCO24 #mmsm
Timothy Schmidt, MD retweeted
Are you a myeloma clinician who orders FISH tests? If so, the CGC Plasma Cell Neoplasm Working Group is interested in your feedback! FISH reports can be confusing and we want to learn about your experiences to help optimize cytogenetic reports. Survey: surveymonkey.com/r/VKTFVTS
Timothy Schmidt, MD retweeted
One of my patients (who labels himself a #PriorAuthSurvivor) diagrammed the unnecessary complexity of trying to get his medication approved on time 👇
Rinse & repeat and this is a cyclic nightmare that has nothing to do with chemo but rather the bureaucracy of US healthcare
Timothy Schmidt, MD retweeted
Luciano Costa, MD, and colleagues review the multiple myeloma treatment landscape and how to implement them into the real-world setting. #mmsm | @End_myeloma @SusanBal9 @mpianko @JoselleCookMD @TMSchmidtMD @bhemato
ow.ly/Cj0V50PqoL9
Timothy Schmidt, MD retweeted
Practical guidelines and recommendations for infection prophylaxis with CAR T and bispecific antibodies in #MultipleMyeloma from the COMMIT Consortium
onlinelibrary.wiley.com/doi/…
@MeeraMohanMD @End_myeloma @rajshekharucms @SusanBal9 @nsc_natalie @BerdejaJesus #mmsm
Timothy Schmidt, MD retweeted
Humoral immune reconstitution following daratumumab, carfilzomib, lenalidomide, & dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and MRD-response-adapted treatment cessation
onlinelibrary.wiley.com/doi/…
@End_myeloma
@TMSchmidtMD
#mmsm
Timothy Schmidt, MD retweeted
Chromosome 1 abnormalities are associated with worse outcomes in #MultipleMyeloma.
In the retrospective analysis by Mohan et al, the combination of both gain(1q21) and del(1p13.3) had a greater impact on outcomes compared to either abnormality on its own.
Read an accompanying editorial by Timothy Schmidt (@UWCarbone):
acsjournals.onlinelibrary.wi…
Combined abnormalities of del (1p13.3) / 1q21gain or amp was significantly worse compared to del(1p13.3) alone and 1q21gain or 1q21 amp alone in #MultipleMyeloma (MM). This identifies a subset of MM patients with poor clinical outcomes.
acsjournals.onlinelibrary.wi…
@OncoAlert
CC: @AjayNookaMD
Timothy Schmidt, MD retweeted
WBCRI is excited to continue recruiting tenure-track basic and translational scientists/scholars in the hematopoiesis and blood cancer fields: jobs.sciencecareers.org/job/… @ASH_hematology @AACR @ISEHSociety @UWCarbone

































